PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients
Naing et al.
Cancer Cell
November 2018
Authors and Affiliates
Naing A1, Infante JR2, Papadopoulos KP3, Chan IH4, Shen C5, Ratti NP4, Rojo B4, Autio KA5, Wong DJ6, Patel MR7, Ott PA8, Falchook GS9, Pant S10, Hung A4, Pekarek KL4, Wu V4, Adamow M5, McCauley S4, Mumm JB4, Wong P5, Van Vlasselaer P4, Leveque J4, Tannir NM1, Oft M11.
1 MD Anderson Cancer Center, Houston, TX, USA.
2 Sarah Cannon Research Institute / Tennessee Oncology, PLLC, Nashville, TN, USA.
3 START Center for Cancer Care, San Antonio, TX, USA.
4ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA.
5Memorial Sloan Kettering Cancer Center, New York, NY, USA.
6 University of California Los Angeles (UCLA), Los Angeles, CA, USA.
7 Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL, USA.
8 Dana-Farber Cancer Institute, Boston, MA, USA.
9 Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.
10 Oklahoma University, Oklahoma City, OK, USA.
11 ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA. Electronic address: martinoft@gmail.com.